Moderate to severe psoriasis patients' subjective future expectations regarding health-related quality of life and longevity

Journal of the European Academy of Dermatology and Venereology

Volumn 29, Issue 7, 2015, Pages 1398-1405

  Rencz, F ^a,b   Hollo P ^c   Karpati S ^c   Pentek M ^a   Remenyik, E ^d   Szegedi, A ^d   Balogh, O ^a   Heredi E ^d   Herszenyi K ^c   Jokai H ^c   Brodszky, V ^a   Gulacsi L ^a  

^a Institute of Data Analytics and Information Systems   (Hungary)

^b SEMMELWEIS UNIVERSITY OF MEDICINE   (Hungary)

^c SEMMELWEIS UNIVERSITY   (Hungary)

^d UNIVERSITY OF DEBRECEN   (Hungary)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ANXIETY; ARTICLE; CHRONIC DISEASE; CLINICAL FEATURE; CROSS-SECTIONAL STUDY; DEPRESSION; DISEASE SEVERITY; EQ 5D SCORE; EXPECTATION; FEMALE; GENDER; HEALTH BEHAVIOR; HUMAN; INVERSE PSORIASIS; LIFE EXPECTANCY; LONGEVITY; MAJOR CLINICAL STUDY; MALE; NAIL PSORIASIS; PAIN; PATIENT COMFORT; PATIENT COMPLIANCE; PRIORITY JOURNAL; PSORIASIS; PSORIASIS VULGARIS; PSORIATIC ARTHRITIS; PUSTULOSIS PALMOPLANTARIS; QUALITY OF LIFE; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL (TOPIC); SCALP; SCORING SYSTEM; AGED; CLINICAL TRIAL; HEALTH STATUS; MIDDLE AGED; MULTICENTER STUDY; PSYCHOLOGY; SEVERITY OF ILLNESS INDEX; VERY ELDERLY;

AGED; AGED, 80 AND OVER; CROSS-SECTIONAL STUDIES; FEMALE; HEALTH STATUS; HUMANS; LONGEVITY; MALE; MIDDLE AGED; PSORIASIS; QUALITY OF LIFE; SEVERITY OF ILLNESS INDEX; SURVEYS AND QUESTIONNAIRES;

EID: 84933180407     PISSN: 09269959     EISSN: 14683083     Source Type: Journal    
DOI: 10.1111/jdv.12884     Document Type: Article

References (32)

1. Gulliver W,. Long-term prognosis in patients with psoriasis. Br J Dermatol 2008; 159 (Suppl. 2): 2-9.
2. Puig L, Kirby B, Mallbris L, Strohal R,. Psoriasis beyond the skin: a review of the literature on cardiometabolic and psychological co-morbidities of psoriasis. Eur J Dermatol 2014; 24: 305-311.
3. Abuabara K, Azfar RS, Shin DB, Neimann AL, Troxel AB, Gelfand JM,. Cause-specific mortality in patients with severe psoriasis: a population-based cohort study in the U.K. Br J Dermatol 2010; 163: 586-592.
4. de Korte J, Sprangers MA, Mombers FM, Bos JD,. Quality of life in patients with psoriasis: a systematic literature review. J Investig Dermatol Symp Proc 2004; 9: 140-147.
5. Kimball AB, Gieler U, Linder D, Sampogna F, Warren RB, Augustin M,. Psoriasis: is the impairment to a patient's life cumulative? J Eur Acad Dermatol Venereol 2010; 24: 989-1004.
6. Mattei PL, Corey KC, Kimball AB,. Cumulative life course impairment: evidence for psoriasis. Curr Probl Dermatol 2013; 44: 82-90.
7. Augustin M,. Cumulative life course impairment: identifying patients at risk. Curr Probl Dermatol 2013; 44: 74-81.
8. Jobling R, Naldi L,. Assessing the impact of psoriasis and the relevance of qualitative research. J Invest Dermatol 2006; 126: 1438-1440.
9. Bhatti ZU, Finlay AY, Bolton CE, et al,. Chronic disease influences over 40 major life-changing decisions (MLCDs): a qualitative study in dermatology and general medicine. J Eur Acad Dermatol Venereol 2013; 28: 1344-1355.
10. Uhlenhake EE, Kurkowski D, Feldman SR,. Conversations on psoriasis-what patients want and what physicians can provide: a qualitative look at patient and physician expectations. J Dermatolog Treat 2010; 21: 6-12.
11. Mrowietz U, Kragballe K, Reich K, et al,. Definition of treatment goals for moderate to severe psoriasis: a European consensus. Arch Dermatol Res 2011; 303: 1-10.
12. Heredi E, Rencz F, Balogh O, et al,. Exploring the relationship between EQ-5D, DLQI and PASI, and mapping EQ-5D utilities: a cross-sectional study in psoriasis from Hungary. Eur J Health Econ 2014; 15 (Suppl. 1): S111-S119.
13. Balogh O, Brodszky V, Gulacsi L, et al,. Cost-of-illness in patients with moderate to severe psoriasis: a cross-sectional survey in Hungarian dermatological centres. Eur J Health Econ 2014; 15 (Suppl. 1): S101-S109.
14. EuroQol G,. EuroQol: a new facility for the measurement of health-related quality of life. Health Policy 1990; 16: 199-208.
15. Bronsard V, Paul C, Prey S, et al,. What are the best outcome measures for assessing quality of life in plaque type psoriasis? A systematic review of the literature. J Eur Acad Dermatol Venereol 2010; 24 (Suppl. 2): 17-22.
16. Finlay AY, Khan GK,. Dermatology Life Quality Index (DLQI): a simple practical measure for routine clinical use. Clin Exp Dermatol 1994; 19: 210-216.
17. Lewis V, Finlay AY,. 10 years experience of the Dermatology Life Quality Index (DLQI). J Investig Dermatol Symp Proc 2004; 9: 169-180.
18. Brouwer WB, van Exel NJ,. Expectations regarding length and health related quality of life: some empirical findings. Soc Sci Med 2005; 61: 1083-1094.
19. Pentek M, Brodszky V, Gulacsi AL, et al,. Subjective expectations regarding length and health-related quality of life in Hungary: results from an empirical investigation. Health Expect 2014; 17: 696-709.
20. Pentek M, Gulacsi L, Rojkovich B, Brodszky V, van Exel J, Brouwer WB,. Subjective health expectations at biological therapy initiation: a survey of rheumatoid arthritis patients and rheumatologists. Eur J Health Econ 2014; 15 (Suppl. 1): S83-S92.
21. Hungarian Central Statistical Office, Statistics Database. Life table of the population of Hungary. [WWW document]. URL http://www.ksh.hu/docs/hun/xstadat/xstadat-hosszu/h-wdsd001b.html (last accessed: 11 August 2014).
22. Miniszewska J, Juczynski Z, Ograczyk A, Zalewska A,. Health-related quality of life in psoriasis: important role of personal resources. Acta Derm Venereol 2013; 93: 551-556.
23. Szende A, Nemeth R,. [ Health-related quality of life of the Hungarian population ]. Orv Hetil 2003; 144: 1667-1674.
24. Shikiar R, Willian MK, Okun MM, Thompson CS, Revicki DA,. The validity and responsiveness of three quality of life measures in the assessment of psoriasis patients: results of a phase II study. Health Qual Life Outcomes 2006; 4: 71.
25. Luger TA, Barker J, Lambert J, et al,. Sustained improvement in joint pain and nail symptoms with etanercept therapy in patients with moderate-to-severe psoriasis. J Eur Acad Dermatol Venereol 2009; 23: 896-904.
26. Reich K, Segaert S, Van de Kerkhof P, et al,. Once-weekly administration of etanercept 50 mg improves patient-reported outcomes in patients with moderate-to-severe plaque psoriasis. Dermatology 2009; 219: 239-249.
27. Revicki D, Willian MK, Saurat JH, et al,. Impact of adalimumab treatment on health-related quality of life and other patient-reported outcomes: results from a 16-week randomized controlled trial in patients with moderate to severe plaque psoriasis. Br J Dermatol 2008; 158: 549-557.
28. Shikiar R, Heffernan M, Langley RG, Willian MK, Okun MM, Revicki DA,. Adalimumab treatment is associated with improvement in health-related quality of life in psoriasis: patient-reported outcomes from a phase II randomized controlled trial. J Dermatolog Treat 2007; 18: 25-31.
29. Norlin JM, Steen Carlsson K, Persson U, Schmitt-Egenolf M,. Switch to biological agent in psoriasis significantly improved clinical and patient-reported outcomes in real-world practice. Dermatology 2012; 225: 326-332.
30. Gelfand JM, Troxel AB, Lewis JD, et al,. The risk of mortality in patients with psoriasis: results from a population-based study. Arch Dermatol 2007; 143: 1493-1499.
31. Ahlehoff O, Skov L, Gislason G, et al,. Cardiovascular disease event rates in patients with severe psoriasis treated with systemic anti-inflammatory drugs: a Danish real-world cohort study. J Intern Med 2013; 273: 197-204.
32. Lawrence BS,. Organizational age norms: why is it so hard to know one when you see one? Gerontologist 1996; 36: 209-220.